All In Biotech

Drug Trial Radar · NCT05067283

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

830

Planned (sponsor's estimate)

Start

Dec 17, 2021

Primary completion

Feb 25, 2030

Study completion Feb 25, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.

Conditions

  • Advanced Solid Tumors

Interventions

  • CalderasibDrug

    Oral dose

  • PembrolizumabBiological

    Intravenous infusion of 200 mg

  • carboplatinDrug

    Per label

  • pemetrexedDrug

    Per label

  • cetuximabBiological

    Per label

  • oxaliplatinDrug

    Per label

  • leucovorinDrug

    Per label

  • 5-fluorouracilDrug

    Per label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to ~21 days
  2. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to ~56 months
  3. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to ~56 months

Locations

75 sites in 21 countries. Site status is shown where the registry gives one.

  • Moffitt Cancer Center ( Site 0261)

    Tampa, Florida · Recruiting

  • START Midwest ( Site 0267)

    Grand Rapids, Michigan · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260)

    Hackensack, New Jersey · Recruiting

  • Laura and Isaac Perlmutter Cancer Center ( Site 0270)

    New York, New York · Completed

  • NEXT Virginia ( Site 0271)

    Fairfax, Virginia · Recruiting

  • MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0262)

    Milwaukee, Wisconsin · Recruiting

  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0438)

    La Rioja, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0434)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Sanatorio Parque ( Site 0456)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Chris O'Brien Lifehouse ( Site 0002)

    Camperdown, New South Wales, Australia · Recruiting

  • Liverpool Hospital-Medical Oncology ( Site 0001)

    Liverpool, New South Wales, Australia · Recruiting

  • Westmead Hospital ( Site 0006)

    Westmead, New South Wales, Australia · Recruiting

  • Monash Health-Oncology Research ( Site 0003)

    Clayton, Victoria, Australia · Recruiting

  • Cross Cancer Institute ( Site 0033)

    Edmonton, Alberta, Canada · Recruiting

  • The Moncton Hospital ( Site 0037)

    Moncton, New Brunswick, Canada · Recruiting

  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0030)

    Hamilton, Ontario, Canada · Recruiting

  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0036)

    Kingston, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0032)

    Toronto, Ontario, Canada · Recruiting

  • James Lind Centro de Investigacion del Cancer ( Site 0043)

    Temuco, Araucania, Chile · Completed

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0041)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • FALP-UIDO ( Site 0040)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0042)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Beijing Friendship Hospital Affiliate of Capital University-Oncology ( Site 0417)

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital ( Site 0419)

    Fuzhou, Fujian, China · Recruiting

  • Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 0413)

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen University Cancer Center-Internal medicine ( Site 0415)

    Guangzhou, Guangdong, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0418)

    Wuhan, Hubei, China · Recruiting

  • Jilin Cancer Hospital-oncology department ( Site 0412)

    Changchun, Jilin, China · Completed

  • Shanghai Chest Hospital-Oncology department ( Site 0410)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai East Hospital ( Site 0416)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhejiang Cancer Hospital-Thoracic oncology ( Site 0411)

    Hangzhou, Zhejiang, China · Recruiting

  • Odense Universitetshospital-Department of oncology ( Site 0421)

    Odense, Region Syddanmark, Denmark · Recruiting

  • Rambam Health Care Campus-Oncology ( Site 0090)

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center-Oncology ( Site 0092)

    Jerusalem, Israel · Recruiting

  • Hadassah Medical Center-Oncology ( Site 0094)

    Jerusalem, Israel · Recruiting

  • Meir Medical Center. ( Site 0091)

    Kfar Saba, Israel · Recruiting

  • Sheba Medical Center-ONCOLOGY ( Site 0093)

    Ramat Gan, Israel · Recruiting

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0110)

    Naples, Italy · Recruiting

  • Humanitas ( Site 0113)

    Rozzano, Lombardy, Italy · Recruiting

  • ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 0111)

    Siena, Tuscany, Italy · Recruiting

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.